… The INSPIRE investigators randomized 826 patients to receive either Interferon-γ1b (IFN-γ1b)
or placebo in a 2: 1 ratio for up to 96 weeks. This is a very interesting and timely, large …

… The dose was selected based on the findings of the idiopathic pulmonary fibrosis trials and
doses of IFN-1b used in the treatment of chronic granulomatous disease. It is unlikely that …

… treatment of scleroderma-related lung fibrosis. Three studies have been recently published
out of the Mayo Clinic using colchicine to treat idiopathic pulmonary fibrosis… of interferon γ1b (…

… Pulmonary fibrosis is often the end stage of chronic, persistent, low-level lung injury, either
… The most severe form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF), a disease …

… of data from the placebo group of a randomized, controlled trial evaluating interferon-γ1b. …
Idiopathic pulmonary fibrosis was the primary cause of death in 89% of patients who died, and …

… for the investigation of etanercept for the treatment of IPF [29]. R… [30] studied the use of
interferon-γ1b in a phase III study of … in overall survival of IPF patients with interferon- γ1b [30]. …

… from patients with idiopathic pulmonary fibrosis are found … authors showed that treatment
with interferon-γ1b decreased the … factor-β1 during the fibrotic process. This preliminary study …

… One of the most prevalent is idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonitis.
Current epidemiology studies 1 suggests that IPF is more common in male subjects, with …

… or inconclusive but have contributed to the evolution of IPF treatment. The first influential trial
was the negative interferon-γ1b trial,[4] which established that adequately powered double-…

Idiopathic pulmonary fibrosis (IPF) is an under-recognised, rare, progressive disease of the
lungs with unknown aetiology and high mortality. The currently advocated pathogenic …